Long-Term Result of A Multicenter Clinical Study of Cetuximab Combined with Intensity Modulated Radiotherapy (imrt) Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Npc).
Chun-yan Chen,Chong Zhao,Li Gao,Jin-yi Lang,Jian-ji Pan,Chao-su Hu,Feng Jin,Ren-sheng Wang,Conghua Xie,Tongyu Lin,Tai-xiang Lu
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.e17020
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:e17020 Background: To evaluate the long term treatment outcome of cetuximab combined with IMRT + concurrent cisplatin in patients with locoregionally advanced NPC in a multicenter clinical study. Methods: Primary NPC patients with stage III - IVb disease were enrolled. The planned dose of IMRT to GTV was 66 - 75.9 Gy in 30 - 33 fractions. Cisplatin and cetuximab were given concurrently. The treatment response was evaluated according to RECIST 1.0 criteria, and adverse events (AEs) were graded according to CTCAE v3.0. Results: From July 2008 to April 2009, 100 patients were enrolled. Besides two cases of mucositis, no other grade 4 AEs were observed during treatment, and no toxic death was observed. With a median follow-up of 4.9 years, 5-year OS, disease-free survival, relapse-free survival (RFS), and distant metastasis-free survival (DMFS) was 82.1%, 69.0%, 74.9% and 75.2%, respectively. Multivariate analysis showed that only masticator space invasion was the prognostic factor for OS (p = 0.0232, HR = 6.64, 95%CI: 1.295～34.039). Within the follow-up period, nine cases of recurrence at the nasopharynx cavity and five at cervical lymph nodes occurred. No statistically significant difference existed among clinical stage III, IVa and IVb for OS or RFS. Distant metastasis occurred in six patients including liver, lung and bone metastasis. For DMFS, only clinical stage was with marginal significance as the prognostic factor (p = 0.0908, HR = 3.06, 95%CI: 0.837～11.161). Long-term AEs of this combined modality treatment mainly consisted of xerostomia, hearing loss, tympanitis, cervical fibrosis, trismus and radiation encephalopathy, etc. Dry mouth and hearing loss were observed in 74% and 57% patients, respectively. Only 12% patient experienced trismus. The incidence of radiation-related encephalopathy was 10%. Conclusions: For locoregionally advanced NPC, the combined treatment modality of IMRT + concurrent chemotherapy + cetuximab was well tolerated. Long-term OS, loco-regional control rate and DMFS at 5 year were very encouraging, with no significant difference among different clinical stage. Clinical trial information: NCT00700440.